Brief: Amneal Pharmaceuticals Says Crexont Commercial Launch Planned In September 2024
07/08/2024 23:25
Aug 7 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O :
* AMNEAL RECEIVES U.S. FDA APPROVAL FOR IPX203 FOR TREATMENT
OF
PARKINSON’S DISEASE TO BE LAUNCHED AS CREXONT® (CARBIDOPA AND
LEVODOPA) EXTENDED-RELEASE CAPSULES
* AMNEAL PHARMACEUTICALS INC - CREXONT COMMERCIAL LAUNCH
PLANNED
IN SEPTEMBER 2024
Source text for Eikon: ID:nBw1gQTlQa
Further company coverage: AMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study